Literature DB >> 31441045

Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Ibrahim Aldoss1, Jianying Zhang2, Raju Pillai3, Geoffrey Shouse1, James F Sanchez1, Matthew Mei1, Ryotaro Nakamura1, Anthony S Stein1, Stephen J Forman1, Guido Marcucci1, Vinod Pullarkat1.   

Abstract

Entities:  

Keywords:  TP53; acute myeloid leukaemia; decitabine; hypomethylating agents; venetoclax

Mesh：

Substances：

Year:  2019        PMID： 31441045      PMCID： PMC6786919          DOI： 10.1111/bjh.16166

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Authors:  D A Sallman; R Komrokji; C Vaupel; T Cluzeau; S M Geyer; K L McGraw; N H Al Ali; J Lancet; M J McGinniss; S Nahas; A E Smith; A Kulasekararaj; G Mufti; A List; J Hall; E Padron
Journal:  Leukemia       Date:  2015-10-30       Impact factor: 11.528

2.  Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Authors:  Ibrahim Aldoss; Dongyun Yang; Ahmed Aribi; Haris Ali; Karamjeet Sandhu; Monzr M Al Malki; Matthew Mei; Amandeep Salhotra; Samer Khaled; Ryotaro Nakamura; David Snyder; Margaret O'Donnell; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

3.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

Authors:  Frank G Rücker; Richard F Schlenk; Lars Bullinger; Sabine Kayser; Veronica Teleanu; Helena Kett; Marianne Habdank; Carla-Maria Kugler; Karlheinz Holzmann; Verena I Gaidzik; Peter Paschka; Gerhard Held; Marie von Lilienfeld-Toal; Michael Lübbert; Stefan Fröhling; Thorsten Zenz; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Peter Lichter; Konstanze Döhner; Hartmut Döhner
Journal:  Blood       Date:  2011-12-20       Impact factor: 22.113

4.  The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Authors:  Mary Ann Anderson; Jing Deng; John F Seymour; Constantine Tam; Su Young Kim; Joshua Fein; Lijian Yu; Jennifer R Brown; David Westerman; Eric G Si; Ian J Majewski; David Segal; Sari L Heitner Enschede; David C S Huang; Matthew S Davids; Anthony Letai; Andrew W Roberts
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  A novel hierarchical prognostic model of AML solely based on molecular mutations.

Authors:  Vera Grossmann; Susanne Schnittger; Alexander Kohlmann; Christiane Eder; Andreas Roller; Frank Dicker; Christoph Schmid; Clemens-Martin Wendtner; Peter Staib; Hubert Serve; Karl-Anton Kreuzer; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach
Journal:  Blood       Date:  2012-08-20       Impact factor: 22.113

6.  Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.

Authors:  Lene Sofie Granfeldt Østgård; Bruno C Medeiros; Henrik Sengeløv; Mette Nørgaard; Mette Klarskov Andersen; Inge Høgh Dufva; Lone Smidstrup Friis; Eigil Kjeldsen; Claus Werenberg Marcher; Birgitte Preiss; Marianne Severinsen; Jan Maxwell Nørgaard
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

7.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  John S Welch; Allegra A Petti; Christopher A Miller; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Jack D Baty; Eric J Duncavage; Bevan Tandon; Yi-Shan Lee; Lukas D Wartman; Geoffrey L Uy; Armin Ghobadi; Michael H Tomasson; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Amanda F Cashen; Mark A Schroeder; Meagan A Jacoby; Sharon E Heath; Kierstin Luber; Megan R Janke; Andrew Hantel; Niloufer Khan; Madina J Sukhanova; Randall W Knoebel; Wendy Stock; Timothy A Graubert; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

8.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

9.  TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.

Authors:  Chi Young Ok; Keyur P Patel; Guillermo Garcia-Manero; Mark J Routbort; Jie Peng; Guilin Tang; Maitrayee Goswami; Ken H Young; Rajesh Singh; L Jeffrey Medeiros; Hagop M Kantarjian; Rajyalakshmi Luthra; Sa A Wang
Journal:  J Hematol Oncol       Date:  2015-05-08       Impact factor: 17.388

10.  COSMIC: the Catalogue Of Somatic Mutations In Cancer.

Authors:  John G Tate; Sally Bamford; Harry C Jubb; Zbyslaw Sondka; David M Beare; Nidhi Bindal; Harry Boutselakis; Charlotte G Cole; Celestino Creatore; Elisabeth Dawson; Peter Fish; Bhavana Harsha; Charlie Hathaway; Steve C Jupe; Chai Yin Kok; Kate Noble; Laura Ponting; Christopher C Ramshaw; Claire E Rye; Helen E Speedy; Ray Stefancsik; Sam L Thompson; Shicai Wang; Sari Ward; Peter J Campbell; Simon A Forbes
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971
  10 in total
  11 in total

1.  Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.

Authors:  Brian J Ball; Christopher A Famulare; Eytan M Stein; Martin S Tallman; Andriy Derkach; Mikhail Roshal; Saar I Gill; Benjamin M Manning; Jamie Koprivnikar; James McCloskey; Rebecca Testi; Thomas Prebet; Najla H Al Ali; Eric Padron; David A Sallman; Rami S Komrokji; Aaron D Goldberg
Journal:  Blood Adv       Date:  2020-07-14

Review 2.  Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?

Authors:  Rory M Shallis; Jan P Bewersdorf; Maximilian F Stahl; Stephanie Halene; Amer M Zeidan
Journal:  Cancers (Basel)       Date:  2022-05-14       Impact factor: 6.575

Review 3.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

Review 4.  Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.

Authors:  Naseema Gangat; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2020-11-23       Impact factor: 11.037

5.  Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.

Authors:  Maansi Joshi; Joselle Cook; Kristen McCullough; Ahmad Nanaa; Naseema Gangat; James M Foran; Hemant S Murthy; Mohamed A Kharfan-Dabaja; Lisa Sproat; Jeanne Palmer; Animesh Pardanani; Ayalew Tefferi; Kebede Begna; Michelle Elliot; Aref Al-Kali; Mrinal Patnaik; Mithun V Shah; William J Hogan; Mark R Litzow; Hassan B Alkhateeb
Journal:  Blood Cancer J       Date:  2021-03-04       Impact factor: 11.037

Review 6.  Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?

Authors:  Serena Brancati; Lucia Gozzo; Giovanni Luca Romano; Calogero Vetro; Ilaria Dulcamare; Cinzia Maugeri; Marina Parisi; Laura Longo; Daniela Cristina Vitale; Francesco Di Raimondo; Filippo Drago
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

7.  How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.

Authors:  Abhishek Maiti; Marina Y Konopleva
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

Review 8.  Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments.

Authors:  Eric M Granowicz; Brian A Jonas
Journal:  Onco Targets Ther       Date:  2022-04-21       Impact factor: 4.345

Review 9.  Venetoclax resistance: mechanistic insights and future strategies.

Authors:  Faustine Ong; Kunhwa Kim; Marina Y Konopleva
Journal:  Cancer Drug Resist       Date:  2022-05-06

Review 10.  Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies.

Authors:  Mila S Griffioen; David C de Leeuw; Jeroen J W M Janssen; Linda Smit
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.